Literature DB >> 23572512

Negative regulation of p53 by Ras superfamily protein RBEL1A.

Ki Lui1, Jie An, Joanne Montalbano, Jingxue Shi, Chad Corcoran, Qin He, Hong Sun, M Saeed Sheikh, Ying Huang.   

Abstract

We had previously reported that RBEL1A, a novel Ras-like GTPase, was overexpressed in multiple human malignancies and that its depletion suppressed cell growth. However, the underlying molecular mechanism remained to be elucidated. Here we report that depletion of endogenous RBEL1A results in p53 accumulation due to increased p53 half-life whereas increased expression of RBEL1A reduces p53 levels under unstressed and genotoxic stress conditions. RBEL1A directly interacts with p53 and MDM2, and strongly enhances MDM2-dependent p53 ubiquitylation and degradation. We also found that RBEL1A modulation of p53 ubiquitylation by MDM2 does not depend on its GTPase activity. We have also defined the p53 oligomeric domain and RBEL1A GTPase domain to be the crucial regions for p53-RBEL1A interactions. Importantly, we have found that RBEL1A strongly interferes with p53 transactivation function; thus our results indicate that RBEL1A appears to function as a novel p53 negative regulator that facilitates MDM2-dependent p53 ubiquitylation and degradation.

Entities:  

Keywords:  GTPase; MDM2; Ubiquitylation, Ras superfamily; p53 tumor suppressor

Mesh:

Substances:

Year:  2013        PMID: 23572512      PMCID: PMC3679486          DOI: 10.1242/jcs.118117

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  24 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Inactivation of the p53-homologue p73 by the mdm2-oncoprotein.

Authors:  M Dobbelstein; S Wienzek; C König; J Roth
Journal:  Oncogene       Date:  1999-03-25       Impact factor: 9.867

Review 3.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

4.  Molecular cloning and functional study of rat estrogen receptor-related receptor gamma in rat prostatic cells.

Authors:  Ki Lui; Yu Huang; H L Choi; Shan Yu; K B Wong; Shiuan Chen; Franky L Chan
Journal:  Prostate       Date:  2006-11-01       Impact factor: 4.104

5.  Identification and characterization of RBEL1 subfamily of GTPases in the Ras superfamily involved in cell growth regulation.

Authors:  JoAnne Montalbano; Ki Lui; M Saeed Sheikh; Ying Huang
Journal:  J Biol Chem       Date:  2009-05-11       Impact factor: 5.157

6.  Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.

Authors:  Chad A Corcoran; JoAnne Montalbano; Hong Sun; Qin He; Ying Huang; M Saeed Sheikh
Journal:  J Biol Chem       Date:  2009-05-29       Impact factor: 5.157

7.  Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.

Authors:  P H Kussie; S Gorina; V Marechal; B Elenbaas; J Moreau; A J Levine; N P Pavletich
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

8.  Interaction of p53 with the human Rad51 protein.

Authors:  S Buchhop; M K Gibson; X W Wang; P Wagner; H W Stürzbecher; C C Harris
Journal:  Nucleic Acids Res       Date:  1997-10-01       Impact factor: 16.971

Review 9.  MDM2 inhibitors for cancer therapy.

Authors:  Lyubomir T Vassilev
Journal:  Trends Mol Med       Date:  2006-11-28       Impact factor: 11.951

10.  Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation.

Authors:  R Rong; L Y Jiang; M S Sheikh; Y Huang
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

View more
  18 in total

1.  A novel prognostic marker of non-small cell lung cancer: chromosome 9 open reading frame 86 (C9orf86).

Authors:  Katsuhiro Yoshimura; Murat Osman; Yusuke Inoue; Takafumi Suda; Haruhiko Sugimura
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Rab-like protein 1 A is upregulated by cisplatin treatment and partially inhibits chemoresistance by regulating p53 activity.

Authors:  Changjin Chen; Ziyi Zhao; Shiyun Tang; Cuiwei Zhang
Journal:  Oncol Lett       Date:  2018-07-24       Impact factor: 2.967

3.  RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Authors:  Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

4.  Negative regulation of RNA-binding protein HuR by tumor-suppressor ECRG2.

Authors:  C Lucchesi; M S Sheikh; Y Huang
Journal:  Oncogene       Date:  2015-10-05       Impact factor: 9.867

5.  RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.

Authors:  Shaikamjad Umesalma; Courtney A Kaemmer; Jordan L Kohlmeyer; Blake Letney; Angela M Schab; Jacqueline A Reilly; Ryan M Sheehy; Jussara Hagen; Nitija Tiwari; Fenghuang Zhan; Mariah R Leidinger; Thomas M O'Dorisio; Joseph Dillon; Ronald A Merrill; David K Meyerholz; Abbey L Perl; Bart J Brown; Terry A Braun; Aaron T Scott; Timothy Ginader; Agshin F Taghiyev; Gideon K Zamba; James R Howe; Stefan Strack; Andrew M Bellizzi; Goutham Narla; Benjamin W Darbro; Frederick W Quelle; Dawn E Quelle
Journal:  J Clin Invest       Date:  2019-03-04       Impact factor: 14.808

Review 6.  The role of human cervical cancer oncogene in cancer progression.

Authors:  Xin-Yu Li; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

7.  RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Casey Pulliam; Chandra K Maharjan; Allison Moreno Samayoa; Heather J Major; Kendall E Cornick; Vickie Knepper-Adrian; Rajesh Khanna; Jessica C Sieren; Mariah R Leidinger; David K Meyerholz; K D Zamba; Jill M Weimer; Rebecca D Dodd; Benjamin W Darbro; Munir R Tanas; Dawn E Quelle
Journal:  Clin Cancer Res       Date:  2020-02-21       Impact factor: 12.531

8.  Transcriptomic and Quantitative Proteomic Profiling Reveals Signaling Pathways Critical for Pancreatic Islet Maturation.

Authors:  Yu-Chin Lien; Kyoung-Jae Won; Rebecca A Simmons
Journal:  Endocrinology       Date:  2020-12-01       Impact factor: 4.736

9.  RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo.

Authors:  Chandra K Maharjan; Shaikamjad Umesalma; Courtney A Kaemmer; Viviane P Muniz; Casey Bauchle; Sarah L Mott; K D Zamba; Patrick Breheny; Mariah R Leidinger; Benjamin W Darbro; Samuel B Stephens; David K Meyerholz; Dawn E Quelle
Journal:  Biomedicines       Date:  2021-06-02

10.  RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Shaikamjad Umesalma; Francoise A Gourronc; Aloysius J Klingelhutz; Dawn E Quelle
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.